Melike Özçelik

ORCID: 0000-0003-0406-715X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Research Studies
  • Cancer Treatment and Pharmacology
  • Lung Cancer Treatments and Mutations
  • Neuroendocrine Tumor Research Advances
  • HER2/EGFR in Cancer Research
  • Gastrointestinal Tumor Research and Treatment
  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Lung Cancer Diagnosis and Treatment
  • Glioma Diagnosis and Treatment
  • Cancer-related Molecular Pathways
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Pancreatic and Hepatic Oncology Research
  • Peptidase Inhibition and Analysis
  • Cancer Genomics and Diagnostics
  • Cancer Diagnosis and Treatment
  • Colorectal Cancer Surgical Treatments
  • Head and Neck Cancer Studies
  • Cardiac tumors and thrombi
  • Neuroblastoma Research and Treatments
  • Cancer survivorship and care
  • Cancer, Hypoxia, and Metabolism
  • Cutaneous Melanoma Detection and Management

Ümraniye Eğitim ve Araştırma Hastanesi
2019-2025

Sağlık Bilimleri Üniversitesi
2019-2024

Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi
2014-2023

Istanbul University
2023

Marmara University
2016-2022

University of Health Science
2021

Adıyaman University
2019

Education and Research Institute
2015-2016

Muğla University
2016

Gaziantep University
2016

Inherited pathogenic variants account for 5% to 10% of all breast cancer (BC) and colorectal (CRC) cases. Here, we sought profile the in 25 susceptibility genes Turkish population. Germline were screened 732 BC patients, 189 CRC patients 490 cancer-free elderly controls, using next-generation sequencing-based multigene panel testing multiplex ligation-dependent probe amplification testing. Pathogenic detected 17.2% high-risk 26.4% patients. More than 95% these clinically actionable. BRCA1/2...

10.1002/ijc.33199 article EN International Journal of Cancer 2020-07-13

Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase as the first-line standard-of-care for patients hormone receptor-positive, HER2-negative metastatic breast cancer.

10.2217/fon-2022-1287 article EN Future Oncology 2023-03-01

Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare other treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 malignant melanoma who underwent surgery within past 10 years. analyzed effect on disease-free survival (DFS). The mean follow-up 40 months, during which 69 (59.5%) experienced recurrence. Among participants, 64 (56.1%) received...

10.1097/cji.0000000000000508 article EN cc-by-nc-nd Journal of Immunotherapy 2024-02-09

Despite numerous studies on second-line therapies in metastatic pancreatic cancer, there is no randomized study evaluating the efficacy of gemcitabine plus nab-paclitaxel as a treatment. This aims to examine therapy. In this retrospective study, total 218 patients from 23 centers were included. The primary endpoint was progression-free survival (PFS), secondary endpoints included overall (OS), treatment based ECOG performance status (PS), and tumor marker (CEA, CA 19 - 9) levels. with...

10.1038/s41598-025-96157-6 article EN cc-by-nc-nd Scientific Reports 2025-04-05

To evaluate the efficacy and safety of transition from premixed intensive insulin to twice-daily degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus.

10.5114/aoms.2020.93264 article EN cc-by-nc-sa Archives of Medical Science 2020-02-25

Background and Objectives: This investigation aimed to determine the impacts of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive HER2-negative metastatic breast cancer managed palbociclib or ribociclib as either initial subsequent line therapy option. Materials Methods: In this retrospective study, were classified "concurrent PPIs" if PPIs given for at least two-thirds period, "no no during period therapy. Each patient was...

10.3390/medicina59030557 article EN cc-by Medicina 2023-03-12

Abstract Background The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been standard of care in this setting as it improved overall survival (OS) compared to placebo. In real-world practice chemotherapy rechallenge also a preferred option even though supporting evidence not enough. We aim compare efficacy regorafenib and 5-fluorouracil-based (5-FU) third mCRC. Methods retrospective multi-institutional trial, mCRC...

10.1186/s12885-023-11783-5 article EN cc-by BMC Cancer 2024-01-02

Sleep quality is known to be associated with the distressing symptoms of cancer. The purpose this study was analyze impact cancer on insomnia and prevalence sleep-related problems reported by patients lung in Turkey.Assesment Palliative Care Lung Cancer Turkey (ASPECT) study, a prospective multicenter conducted participation 26 centers included all cancer, re-evaluated terms sleep problems, possible association symptoms. Demographic characteristics information about disease were recorded for...

10.5578/tt.67689 article EN Tuberkuloz ve Toraks 2018-12-17

The aim of the study was to evaluate real-world clinical outcomes atezolizumab and bevacizumab (Atez/Bev) as initial therapy for advanced hepatocellular carcinoma (HCC). We retrospectively analyzed 65 patients treated with Atez/Bev HCC from 22 institutions in Turkey between September 2020 March 2023. Responses were evaluated by RECIST v1.1 criteria. median progression-free survival (PFS) overall (OS) calculated using Kaplan–Meier method. Cox regression model employed conduct multivariate...

10.1097/md.0000000000035950 article EN cc-by-nc Medicine 2023-11-10

<b><i>Background:</i></b> Upregulation of caveolin-1 (Cav-1) expression is correlated with histopathological grade and poor prognosis in several human cancers. However, gastric cancer, its clinical utility as a useful prognostic molecular marker remains unclear. <b><i>Methods:</i></b> The importance Cav-1 was retrospectively analyzed by immunohistochemistry 148 patients cancer who had undergone radical gastrectomy....

10.1159/000456620 article EN Oncology Research and Treatment 2017-01-01

<b><i>Objective:</i></b> To investigate the symptoms of lung cancer in Turkey and to evaluate approaches alleviate these symptoms. <b><i>Subjects Methods:</i></b> This study included 1,245 patients from 26 centers Turkey. Demographic characteristics as well information regarding disease treatments were obtained medical records patient interviews. Symptoms evaluated using Edmonton Symptom Assessment Scale (ESAS) graded on a scale between 0 10...

10.1159/000452801 article EN cc-by-nc Medical Principles and Practice 2016-10-24

Concomitant administration of chemotherapy and radiotherapy is currently recognized as the standard treatment in locally advanced inoperable non-small cell lung cancer (NSCLC). Our study aimed to compare efficacy toxicities three different regimens delivered concurrently with radiotherapy. We retrospectively reviewed clinical records patients who received PE (cisplatin, 50 mg/m2, on days 1, 8, 29, 36 plus etoposide, 1 5 29 33), PD (docetaxel, 20 day cisplatin, every week), PC (carboplatin,...

10.1007/s13277-015-4776-1 article EN Tumor Biology 2016-01-11

Most data on prognostic factors for patients with high-grade undifferentiated pleomorphic sarcoma (HGUPS) is obtained from analyses of soft tissue sarcomas. The purpose this study was to evaluate the clinicopathologic features and their impact outcomes specifically in diagnosed HGUPS. In multicenter trial, we retrospectively analyzed 112 who were treated at 12 different institutions Turkey. We collected concerning patients, tumor characteristics, treatment modalities. There 69 males (61.6 %)...

10.1007/s13277-015-4359-1 article EN Tumor Biology 2015-11-09

Backgrounds and Objectives Colorectal cancer is one of the leading causes mortality both globally in our country. In Turkey, we conducted a multicenter investigation into effectiveness second-line treatments real-life data for patients with RAS wild-type metastatic colorectal (NCT04757311). Materials Methods this retrospective analysis, records from 28 centers were collected, histopathological, molecular, clinical characteristics documented. Patients categorized groups based on their...

10.1177/10781552241241004 article EN Journal of Oncology Pharmacy Practice 2024-04-13

Mucosal melanoma (MM) is a rare type of cancer that differs significantly from cutaneous melanoma. In this study, we aimed to evaluate clinical and demographical characteristics, prognoses factors influencing survival, treatment alternatives, features different subtypes the patients. The patients were followed up with treated in centers due their diagnoses MM. We retrospectively analyzed data 107 who diagnosed MM 14 institutions Turkey. mean age was 64.5 years. Of patients, 47 % female 53...

10.1007/s13277-016-5076-0 article EN Tumor Biology 2016-05-12

Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) therapy has been shown to be a well tolerated highly effective regimen for metastatic gastric carcinoma. Herein we investigated the effectiveness of mDCF combination as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma head neck (HNSCC).A total 80 HNSCC who were treated between 2009 2015 enrolled into this study. All 2-6 cycles chemotherapy which consisted docetaxel 60 mg/m2 intravenously (IV) on day 1,...

10.1080/03007995.2016.1257984 article EN Current Medical Research and Opinion 2016-11-05

Purpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients non-adipocytic advanced soft sarcomas. The aim of this retrospective study to evaluate the real life data single-agent pazopanib efficacy safety for Turkish population. Materials methods We evaluated total 103 (41 males, 62 females) who received diagnosis eight centers Turkey, retrospectively....

10.1177/1078155220924075 article EN Journal of Oncology Pharmacy Practice 2020-05-16
Coming Soon ...